@article{220698f5b2964eea88b68d7db27ce0d3,
title = "Long-acting antiretrovirals and HIV treatment adherence",
abstract = "Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV. Long-acting cabotegravir with rilpivirine ART has reduced required dosing frequency from once daily to once every month or every 2 months injections. This new era of long-acting ART, which includes other antiretrovirals and formulations in various stages of clinical development, holds tremendous promise to change the standard of HIV treatment. Although long-acting ART has high potential to be revolutionary in the landscape of HIV care, prevention, and treatment cascade, more data are needed to substantiate its efficacy and cost-effectiveness among patients at risk of non-adherence and across age groups, pregnancy, and post partum. Advocacy efforts and policy changes to optimise a sustained, high-quality, equitable reach of long-acting ART, especially in low-income and middle-income countries where most people living with HIV reside, are needed to realise the full benefits of long-acting ART.",
author = "Nachega, {Jean B.} and Scarsi, {Kimberly K.} and Monica Gandhi and Scott, {Rachel K.} and Mofenson, {Lynne M.} and Moherndran Archary and Sharon Nachman and Eric Decloedt and Geng, {Elvin H.} and Lindsay Wilson and Angeli Rawat and Mellors, {John W.}",
note = "Funding Information: We thank Charles W Flexner (Divisions of Infectious Diseases and Clinical Pharmacology, Johns Hopkins School of Medicine, Baltimore, MD, USA) and Prof Gary Maartens (Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa) for critical review and advice. JBN is supported by the US National Institutes of Health (NIH), National Institutes of Allergy and Infectious Diseases (NIAID) and Fogarty International Center (FIC) grant numbers NIH/FIC 1R25TW011217–01; NIH/FIC 1D43TW010937–01A1; NIH/FIC D43TW011827–01A1; NIH/FIC 1R21TW011706–0; and NIH/NIAID 5U01AI096299–13. KKS is supported by NIH/NICHD grant number R01HD085887. ED is supported by NIH/FIC grant number R21 TW 012185–01; and NIH/NIAID grant number R01AI152119–01. MG is supported by NIH/NIAID grant number 2R01AI098472. JWM is supported by US NIH/NIAID grant numbers UM1 AI106701, UM1 AI126603, UM1 AI164556 and UM1 AI164565, and NCI Contract 75N91019D00024. Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",
year = "2023",
month = may,
doi = "10.1016/S2352-3018(23)00051-6",
language = "English (US)",
volume = "10",
pages = "e332--e342",
journal = "The Lancet HIV",
issn = "2352-3018",
publisher = "Elsevier Limited",
number = "5",
}